Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine.

World journal of gastroenterology - 14 Aug 2007

Chae Hee Bok, Hann Hie-Won

Abstract excerpt

AIM: To identify the factors associated with virologic breakthrough and to select a subgroup of patients who respond well to lamivudine without developing virologic breakthrough (VBT). METHODS: Of 79 patients who had received lamivudine therapy for 9-57 mo, 34 were HBeAg-positive and 45 were HBeAg-negative, 24 developed virologic breakthrough and 55 did not. Clinical and virologic factors were compared between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Lamivudine

Share to Logistic Models

Share to Viral Core Proteins

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 17696226
DOI: 10.3748/wjg.v13.i30.4085
PMCID: PMC4205309

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine.PMID 17696226Read ↗

Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.Semantic proximity Read ↗

Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.Semantic proximity Read ↗

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.Semantic proximity Read ↗

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.Semantic proximity Read ↗

Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B.Semantic proximity Read ↗

Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C.Semantic proximity Read ↗

The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.Semantic proximity Read ↗

Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B.Semantic proximity Read ↗

The effect of HLA-DQB1 alleles on virologic breakthroughs during chronic hepatitis B treatment with genetically low barrier drugs.Semantic proximity Read ↗

Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.Semantic proximity Read ↗

Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants.Semantic proximity Read ↗

Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.